KP Tissue (TSE:KPT) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
KP Tissue Inc. reported robust financial results with a record $1.9 billion in sales and a significant increase in Adjusted EBITDA for the fiscal year 2023, alongside a solid Q4 performance boasting a 37.9% rise in Adjusted EBITDA and a slight increase in net income. The company’s growth was fueled by market share gains in the Consumer segment, strategic investments, and operational efficiency. KP Tissue is poised to continue this momentum into 2024, expecting stable margins and sustained EBITDA in Q1.
For further insights into TSE:KPT stock, check out TipRanks’ Stock Analysis page.